<乌鸦传媒>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
<乌鸦传媒>Breast Ultrasound Recs May Not Be Targeting the Right Women It's not just dense breasts that matter, researchers say Jun 12, 2023
<乌鸦传媒>How Vax Skeptics Sow Doubt; Gun Death Every 11 Minutes; 90210 Star's Cancer Spreads Health news and commentary from around the Web gathered by 乌鸦传媒 staff Jun 08, 2023
<乌鸦传媒>Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost Jun 07, 2023
<乌鸦传媒>How a Medical Recoding May Limit Cancer Patients鈥� Options for Breast Reconstruction Many believe this would restrict women's options for surgery Jun 04, 2023
<乌鸦传媒>Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET Jun 03, 2023
<乌鸦传媒>CDK4/6 Extends Reach Into Early-Stage Breast Cancer Addition of ribociclib to endocrine therapy boosts disease-free survival in high-risk disease Jun 02, 2023
<乌鸦传媒>ASCO Backs Routine ESR1 Testing for Certain Breast Cancers Activity of elacestrant in EMERALD trial "provides strong signal" for guideline update May 18, 2023
<乌鸦传媒>Proposed Breast Cancer Screening Guidelines Are Good, but Not Enough Specifics for older women, Black women, and those with dense breasts are needed May 09, 2023
<乌鸦传媒>Thriving After Cancer Tara Sanft, MD, on how clinicians can support patients through difficult times May 02, 2023 podcast
<乌鸦传媒>Talc-Cancer Lawsuits on Hold; Diet & Prostate Cancer; Active Surveillance Deep Dive News, features, and commentary about cancer-related issues Apr 21, 2023
<乌鸦传媒>Many With Cancer Predisposition Diseases Unaware of Genetic Status Moreover, a significant proportion do not qualify for genetic screening under current guidelines Apr 19, 2023
<乌鸦传媒>Taxane, Anthracycline Combo Most Effective in Reducing Breast Cancer Recurrence Chemotherapy regimens with higher cumulative dose provide greatest benefit Apr 14, 2023
<乌鸦传媒>Local Anesthesia Before Breast Cancer Surgery Improves OS in Randomized Trial Intervention is inexpensive, easy to implement, researchers say Apr 07, 2023
<乌鸦传媒>High Out-of-Pocket Costs Tied to Less Follow-Up After Initial Mammography Plans dominated by copays and deductibles are associated with higher out-of-pocket costs Mar 27, 2023
<乌鸦传媒>Progestin-Only Birth Control Linked to Small Increase in Breast Cancer Risk But risk is similar to combined hormonal contraceptive use Mar 22, 2023
<乌鸦传媒>Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer Choice of agent, post-progression treatment, and resistance mechanisms top unanswered questions Mar 08, 2023
<乌鸦传媒>Understanding of HER2-Low Breast Cancer Continues to Evolve New breast cancer subtype proves challenging to define molecularly, pathologically, clinically Mar 07, 2023
<乌鸦传媒>Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
<乌鸦传媒>'Our Goal Is Not to Omit Radiation Therapy' in Breast Cancer Honing indications for de-escalation of treatment intensity and, yes, selective omission of RT Mar 06, 2023
<乌鸦传媒>Antibody-Drug Conjugates Take Breast Cancer Field by Storm Established role in metastatic disease, may eventually replace chemotherapy Mar 04, 2023
<乌鸦传媒>These Surgeries Made the Sharpest Turns to Outpatient Setting After COVID Several procedures saw significant increases in outpatient volumes Mar 03, 2023
<乌鸦传媒>How to Make Meaningful Moves Toward Health Equity in Cancer Care Addressing the three R's: resources, research, and racism Feb 27, 2023
<乌鸦传媒>Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoe News, features, and commentary about cancer-related issues Feb 24, 2023
<乌鸦传媒>Safe to Omit RT After Lumpectomy in Certain Older Breast Cancer Patients Radiotherapy reduced local recurrence, but showed no effect on OS, distant recurrence Feb 15, 2023
<乌鸦传媒>FDA Greenlights First Drug for ESR1-Mutated Breast Cancer Elacestrant almost doubled PFS versus standard endocrine therapy in advanced ER+/HER2- disease Jan 30, 2023
<乌鸦传媒>MRI-Guided Focused Ultrasound Eases Pain From Bone Metastases More responses with ultrasound, but quality-of-life scores lower vs EBRT in nonrandomized trial Jan 11, 2023
<乌鸦传媒>Genomic Assay May Pinpoint Who Can Skip RT After Breast-Conserving Surgery Patients categorized as low risk with 16-gene signature showed no significant benefit with RT Jan 06, 2023
<乌鸦传媒>Optimizing Treatment for Older Patients With HR+ Low-Risk Breast Cancer Five days of radiotherapy, five years of hormonal therapy, or somewhere in between? Jan 05, 2023
<乌鸦传媒>Mixed Results With Hormonal Strategies for Premenopausal Breast Cancer Exemestane reduced recurrence, metastasis versus tamoxifen, but no survival benefit Dec 20, 2022
<乌鸦传媒>Less Is More Wins Again: Avoiding Node Dissection in Early Breast Cancer First comparison of targeted sentinel node assessment shows no difference in recurrence rates Dec 09, 2022
<乌鸦传媒>Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer In phase III trial, capivasertib benefited patients with or without AKT pathway alterations Dec 09, 2022
<乌鸦传媒>Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations Dec 09, 2022
<乌鸦传媒>Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor Dec 09, 2022
<乌鸦传媒>Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancer Study suggests no increased risk of cancer recurrence versus historical control Dec 09, 2022
<乌鸦传媒>T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancer Trastuzumab deruxtecan improves survival in second- and later-line settings Dec 08, 2022
<乌鸦传媒>Neoadjuvant T-DXd Active in HER2-Low Breast Cancer Response rates on the order of 58-68%, with or without endocrine therapy Dec 08, 2022
<乌鸦传媒>Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancer No improvement in the overall analysis but a hint of benefit in premenopausal patients Dec 08, 2022
<乌鸦传媒>Assay Predicts Breast Cancer Patients Who Will Benefit From Ovarian Suppression Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy Dec 07, 2022
<乌鸦传媒>First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancer Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup Dec 07, 2022
